Biomarkers to optimize the treatment of nicotine dependence

Biomarkers in Medicine

Volumn 5, Issue 6, 2011, Pages 745-761

  Schnoll, Robert A ^b   Leone, Frank T ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

^b NONE

Author keywords

CYP2A6; dopamine; nicotine dependence; nicotine metabolite ratio; pharmacogenetic; smoking; tobacco

Indexed keywords

AMFEBUTAMONE; BIOLOGICAL MARKER; CYTOCHROME P450 2A6; DOPAMINE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINIC RECEPTOR; OPIATE RECEPTOR; PLACEBO; VARENICLINE;

ALLELE; ANKK1 GENE; CHRNB2 GENE; CLINICAL PRACTICE; COMT GENE; CYP2A6 GENE; CYP2B6 GENE; DNA POLYMORPHISM; DOPAMINERGIC SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; GABAERGIC SYSTEM; GENE; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HERITABILITY; HUMAN; LOZENGE; NEUROBIOLOGY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; OPRM1 GENE; PHARMACOGENOMICS; PRIMARY MEDICAL CARE; REVIEW; SLC6A3 GENE; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT INDICATION; TREATMENT RESPONSE; VENTRAL TEGMENTUM; WITHDRAWAL SYNDROME;

BIOLOGICAL MARKERS; DOPAMINE; HUMANS; NICOTINE; PHARMACOGENETICS; RECEPTORS, NICOTINIC; SMOKING; TOBACCO USE DISORDER;

EID: 82755195600     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.91     Document Type: Review

References (126)

1. Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses -United States, 2000-2004. MMWR Morb. Mortal. Wkly Rep. 57, 1226-1228 (2008).
2. United States Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA, USA (2004).
3. Centers for Disease Control and Prevention. Vital signs: current cigarette smoking among adults aged ≥18 years -United States, 2009. MMWR Morb. Mortal. Wkly Rep. 59, 1135-1140 (2010).
4. Centers for Disease Control and Prevention. Cigarette smoking -United States, 1965-2008. MMWR Morb. Mortal. Wkly Rep. 60, 109-113 (2011).
5. Levy DT, Mabry PL, Graham AL, Orleans CT, Abrams DB. Exploring scenarios to dramatically reduce smoking prevalence: a simulation model of the three-part cessation process. Am. J. Public Health 100, 1253-1259 (2010).
6. Pollock JD, Koustova E, Hoffman A, Shurtleff D, Volkow ND. Treatments for nicotine addiction should be a top priority. Lancet 374, 513-514 (2009).
7. Gariti P, Levin S, Whittingham T et al. Why do those who request smoking treatment fail to attend the first appointment? J. Substance Abuse Treat. 35, 62-67 (2008). (Pubitemid 351734599)
8. Dahm JL, Cook E, Baugh K et al. Predictors of enrollment in a smoking cessation clinical trial after eligibility screening. J. Nat. Med. Assoc. 101, 450-455 (2009).
9. Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am. J. Prev. Med. 34, 102-111 (2008).
10. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 99, 29-38 (2004). (Pubitemid 38142221)
11. Schnoll RA, Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Exp. Op. Emerg. Drugs 11, 429-444 (2006). (Pubitemid 44386368)
12. Mifsud JC, Hernandez L, Hoebel BG. Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis. Brain Res. 478, 365-367 (1989). (Pubitemid 19033493)
13. Pidoplichko VI, DeBiasi M, Williams JT, Dani JA. Nicotine activates and desensitizes midbrain dopamine neurons. Nature 390, 401-404 (1997). (Pubitemid 28027320)
14. Rice ME, Cragg SJ. Nicotine amplifies reward-related dopamine signals in striatum. Nat. Neurosci. 7, 583-584 (2004). (Pubitemid 38691894)
15. Rao TS, Correa LD, Adams P, Santori EM, Sacaan AI. Pharmacological characterization of dopamine, norepinephrine and serotonin release in the rat prefrontal cortex by neuronal nicotinic acetylcholine receptor agonists. Brain Res. 990, 203-208 (2003). (Pubitemid 37244076)
16. Nestler EJ. Is there a common molecular pathway for addiction? Nat. Neurosci. 8, 1445-1449 (2005). (Pubitemid 41573654)
17. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl.) 168, 347-358 (2003). (Pubitemid 36920920)
18. Epping-Jordan MP, Watkins SS, Koob GF, Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393, 76-79 (1998). (Pubitemid 28240257)
19. Kalivas PW, Neurotransmitter regulation of dopamine neurons in the ventral tegmental area. Brain Res. Rev. 18, 75-113 (1993). (Pubitemid 23090012)
20. Sesack SR, Pickel VM. Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J. Comp. Neurol. 320, 145-160 (1992).
21. Chen J, Nakamura M, Kawamura T, Takahashi T, Nakahara D. Roles of pedunculopontine tegmental cholinergic receptors in brain stimulation reward in the rat. Psychopharmacology (Berl.) 184, 514-522 (2006). (Pubitemid 43255868)
22. Klink R, de Kerchove d'Exaerde A, Zoli M, Changeux JP. Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J. Neurosci. 21, 1452-1463 (2001). (Pubitemid 32182187)
23. Jones IW, Wonnacott S. Precise localization of alpha7 nicotinic acetylcholine receptors on glutamatergic axon terminals in the rat ventral tegmental area. J. Neurosci. 24, 11244-11252 (2004). (Pubitemid 39658259)
24. Markou A. Neurobiology of nicotine dependence. Philos. Trans. R. Soc. Lond. B Biol. Sci. 363, 3159-3168 (2008).
25. George TP, Weinberger AH. Monoamine oxidase inhibition for tobacco pharmacotherapy. Clin. Pharm. Ther. 83, 619-621 (2008). (Pubitemid 351417061)
26. Dhatt RK, Gudehithlu KP, Wemlinger TA, Tejwani GA, Neff NH, Hadjiconstantinou M. Preproenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine. J. Neurochem. 64, 1878-1883 (1995).
27. Davenport KE, Houdi AA, Van Loon GR. Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain. Neurosci. Lett. 113, 40-46 (1990). (Pubitemid 20175254)
28. Bergevin A, Girardot D, Bourque MJ, Trudeau LE. Presynaptic mu-opioid receptors regulate a late step of the secretory process in rat ventral tegmental area GABAergic neurons. Neuropharmacology 42, 1065-1078 (2002). (Pubitemid 34786559)
29. Ray R, Loughead J, Wang Z et al. Neuroimaging, genetics, and the treatment of nicotine addiction. Behav. Brain Res. 193, 156-169 (2008).
30. Cosgrove K. Imaging receptor changes in human drug abusers. Curr. Top. Behav. Neurosci. 3, 199-217 (2010).
31. Hopfer CJ, Crowley TJ, Hewitt JK. Review of twin and adoption studies of adolescent substance use. J. Am. Acad. Child Adolesc. Psychiatry 42, 710-719 (2003). (Pubitemid 39625057)
32. Li MD, Cheng R, Ma JZ, Swan GE. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 98, 23-31 (2003). (Pubitemid 36044333)
33. Sullivan PF, Kendler KS. The genetic epidemiology of smoking. Nicotine Tob. Res. 1(Suppl. 2), S51-S57 (1999).
34. Vink JM, Willemsen G, Boomsma DI. Heritability of smoking initiation and nicotine dependence. Behav. Genet. 35, 397-406 (2005). (Pubitemid 40848169)
35. Hamilton AS, Lessov-Schlaggar CN, Cockburn MG et al. Gender differences in determinants of smoking initiation and persistence in California twins. Cancer Epidemiol. Biomarkers Prev. 15, 1189-1197 (2006).
36. Osler M, Holst C, Prescott E, Sorensen TI. Influence of genes and family environment on adult smoking behavior assessed in an adoption study. Genet. Epidemiol. 21, 193-200 (2001). (Pubitemid 33021273)
37. Haberstick BC, Timberlake D, Ehringer MA et al. Genes, time to first cigarette and nicotine dependence in a general population sample of young adults. Addiction 102, 655-665 (2007). (Pubitemid 46398839)
38. True WR, Xian H, Scherrer JF et al. Common genetic vulnerability for nicotine and alcohol dependence in men. Arch. Gen. Psychiatry 56, 655-661 (1999). (Pubitemid 29315638)
39. Xian H, Scherrer JF, Madden PA et al. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob. Res. 5, 245-254 (2003). (Pubitemid 36547008)
40. Hardie TL, Moss HB, Lynch KG. Genetic correlations between smoking initiation and smoking behaviors in a twin sample. Addict. Behav. 31, 2030-2037 (2006). (Pubitemid 44548191)
41. Wang J, Li MD. Common and unique biological pathways associated with smoking initiation/progression, nicotine dependence, and smoking cessation. Neuropsychopharmacology 35, 702-719 (2010).
42. Ray R, Schnoll R, Lerman C. Nicotine dependence and pharmacogenetics. In: Handbook of Behavioral Medicine. Steptoe A, Freedland KE, Jennings JR, Llabre MM, Manuck SB, Susman EJ (Eds). Springer, New York, NY, USA, 479-498 (2010).
43. Beirut LJ. Genetic vulnerability and susceptibility to substance dependence. Neuron 69, 618-627 (2011).
44. Thorgeirsson TE, Gudbjartsson DF, Surakka I et al. Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. Nat. Genet. 42, 448-453 (2010).
45. Tobacco and Genetics (TAG) Consortium. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat. Genet. 42, 441-447 (2010).
46. Liu JZ, Tozzi F, Waterworth DM, Pillai SG, Muglia P, Middleton L. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat. Genet. 42, 436-440 (2010).
47. Saccone NL, Schwantes-An TH, Wang JC, Grucza RA, Breslau N, Hatsukami D. Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African and European Americans. Genes Brain Behav. 9, 741-750 (2010).
48. Sturgess JE, George TP, Kennedy JL, Heinz A, Müller DJ. Pharmacogenetics of alcohol, nicotine and drug addiction treatments. Addict. Biol. 16, 357-376 (2011).
49. Kortmann GL, Dobler CJ, Bizarro L, Bau CHD. Pharmacogenetics of smoking cessation therapy. Am. J. Med. Genet. Part B 153B, 17-28 (2009).
50. Fiore MC, Jaen CR, Baker TB et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. US Department of Health and Human Services, Public Health Service, Rockville, MD, USA (2008).
51. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 23, CD000146 (2008).
52. Ray R, Tyndale RF, Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J. Neurogenetics 23, 252-261 (2009).
53. Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, Benowitz NL. Genetic and environmental influences on the ratio of 3′ hydroxycotinine to cotinine in plasma and urine. Pharmacogenet. Genomics 19, 388-398 (2009).
54. Gu DF, Hinks LJ, Morton NE, Day IN. The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann. Hum. Genet. 64, 383-390 (2000). (Pubitemid 32055729)
55. Kubota T, Nakajima-Taniguchi C, Fukuda T et al. CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation. Pharmacogenomics J. 6, 115-119 (2006).
56. Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiol. Biomarkers Prev. 15, 1812-1819 (2006). (Pubitemid 44664253)
57. Dempsey D, Tutka P, Jacob P 3rd et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin. Pharmacol. Ther. 76, 64-72 (2004). (Pubitemid 38844735)
58. Levi M, Dempsey DA, Benowitz NL, Sheiner LB. Prediction methods for nicotine clearance using cotinine and 3-hydroxy-cotinine spot saliva samples. II. Model application. J. Pharmacokinet. Pharmacodyn. 34, 23-34 (2007). (Pubitemid 46122546)
59. Lea RA, Dickson S, Benowitz NL. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J. Anal. Toxicol. 30, 386-389 (2006). (Pubitemid 44274073)
60. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P 3rd. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin. Pharmacol. Ther. 79, 480-488 (2006).
61. Lerman C, Tyndale R, Patterson F et al. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther. 79, 600-608 (2006). (Pubitemid 43817942)
62. Schnoll RA, Patterson F, Wileyto EP et al. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacol. Biochem. Behav. 92, 6-11 (2009).
63. Hutchison KE, Allen DL, Filbey FM et al. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch. Gen. Psychiatry 64, 1078-1086 (2007). (Pubitemid 47360853)
64. Perkins KA, Lerman C, Mercincavage M, Fonte CA, Briski JL. Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch. Cancer Epidemiol. Biomarkers Prev. 18, 2608-2612 (2009).
65. Ray R, Mitra N, Baldwin D et al. Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence. Neuropsychopharmacology 35, 1374-1382 (2010).
66. Thompson J, Thomas N, Singleton A et al. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7, 479-484 (1997). (Pubitemid 27517576)
67. Yudkin P, Munafo M, Hey K et al. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 328, 989-990 (2004). (Pubitemid 38530370)
68. Johnstone EC, Yudkin PL, Hey K et al. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14, 83-90 (2004). (Pubitemid 38253643)
69. Munafo MR, Johnstone EC, Murphy MF, Aveyard P. Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial. Nicotine Tob. Res. 11, 404-407 (2009).
70. Arinami T, Gao M, Hamaguchi H et al. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum. Mol. Genet. 6, 577-582 (1997). (Pubitemid 27142107)
71. Duan J, Wainwright MS, Comeron JM et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 12, 205-216 (2003). (Pubitemid 36204418)
72. Lerman C, Jepson C, Wileyto EP et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31, 231-242 (2006). (Pubitemid 43250960)
73. Dahl JP, Jepson C, Levenson R et al. Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenomics J. 6, 194-199 (2006). (Pubitemid 43811571)
74. David SP, Munafo MR, Murphy MF, Proctor M, Walton RT, Johnstone EC. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation. follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J. 8, 122-128 (2008). (Pubitemid 351411548)
75. Asghari V, Schoots O, van Kats S et al. Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol. Pharmacol. 46, 364-373 (1994). (Pubitemid 24271434)
76. Van Tol HH, Wu CM, Guan HC et al. Multiple dopamine D4 receptor variants in the human population. Nature 358, 149-152 (1992).
77. Chen J, Lipska BK, Halim N et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 75, 807-821 (2004). (Pubitemid 39390488)
78. David SP, Johnstone E, Griffiths SE et al. No association between functional catechol O-methyl transferase 1947A>G polymorphism and smoking initiation, persistent smoking or smoking cessation. Pharmacogenetics 12, 265-268 (2002). (Pubitemid 34596791)
79. Colilla S, Lerman C, Shields PG et al. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet. Genomics 15, 393-398 (2005). (Pubitemid 40835080)
80. Johnstone EC, Elliot KM, David SP et al. Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol. Biomarkers Prev. 16, 1065-1069 (2007). (Pubitemid 46984939)
81. Munafo MR, Johnstone EC, Guo B, Murphy MF, Aveyard P. Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenet. Genomics 18, 121-128 (2008).
82. David SP, Johnstone EC, Churchman M, Aveyard P, Murphy MF, Munafo MR. Pharmacogenetics of smoking cessation in general practice: results from the Patch II and Patch in Practice trials. Nicotine Tob. Res. 13, 157-167 (2011).
83. Zhang Y, Wang D, Johnson AD et al. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 280, 32618-32624 (2005). (Pubitemid 41368304)
84. Ray R, Ruparel K, Newberg A et al. Human mu opioid receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc. Natl Acad. Sci. 108, 9268-9273 (2011).
85. Lerman C, Wileyto EP, Patterson F et al. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 4, 184-192 (2004). (Pubitemid 38786557)
86. Munafo MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC. Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J. 7, 353-361 (2007). (Pubitemid 47471313)
87. Ray R, Jepson C, Wileyto EP et al. Genetic variation in mu opioid receptor interacting proteins and smoking cessation in a nicotine replacement therapy trial. Presented at: Society for Research on Nicotine and Tobacco Annual Meeting. Orlando, FL, USA, 15-18 February, 2006.
88. Munafo MR, Johnstone EC, Wileyto EP, Shields PG, Elliot KM, Lerman C. Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol. Biomarkers Prev. 15, 398-400 (2006). (Pubitemid 43342194)
89. David SP, Munafo MR, Murphy MF, Walton RT, Johnstone EC. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine Tob. Res. 9, 225-231 (2007). (Pubitemid 47009068)
90. David SP, Johnstone EC, Murphy MF et al. Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses. Drug Alcohol Depend. 98, 77-85 (2008).
91. Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict. Biol. 10, 219-231 (2005). (Pubitemid 41306325)
92. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst. Rev. (1), CD000031 (2007).
93. Patterson F, Schnoll R, Wileyto E et al. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin. Pharmacol. Ther. 84, 320-325 (2008).
94. Lerman C, Shields PG, Wileyto EP et al. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12, 627-634 (2002). (Pubitemid 36005672)
95. David SP, Brown RA, Papandonatos GD et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob. Res. 9, 821-833 (2007). (Pubitemid 47190150)
96. Lee AM, Jepson C, Hoffmann E et al. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol. Psychiatry 62, 635-641 (2007). (Pubitemid 47314367)
97. Hesse L, He P, Krishnaswamy S et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14, 225-238 (2004). (Pubitemid 38530514)
98. Conti DV, Lee W, Li D et al. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum. Mol. Genet. 17, 2834-2848 (2008).
99. Heitjan DF, Guo M, Ray R, Wileyto EP, Epstei LH, Lerman C. Identification of pharmacogenetic markers in smoking cessation therapy. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 712-719 (2008).
100. Lerman C, Shields PG, Wileyto EP et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 22, 541-548 (2003). (Pubitemid 37243689)
101. David SP, Strong DR, Munafo MR et al. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob. Res. 9, 1251-1257 (2007). (Pubitemid 350215057)
102. Swan GE, Jack LM, Valdes AM et al. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol. 26, 361-368 (2007). (Pubitemid 46763197)
103. O'Gara C, Stapleton J, Sutherland G et al. Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet. Genomics 17, 61-67 (2007). (Pubitemid 46183792)
104. Leventhal AM, David SP, Brightman M et al. Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J. doi:10.1038/tpj.2010.64 (2010) (Epub ahead of print).
105. Berrettini W, Wileyto EP, Epstein L et al. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol. Psychiatry 61, 111-118 (2007). (Pubitemid 44855744)
106. Gonzales D, Rennard S, Nides M et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296, 47-55 (2006).
107. Jorenby DE, Hays JT, Rigotti N et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296, 56-63 (2006).
108. Aubin HJ, Bobak A, Britton JR et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised, open-label trial. Thorax 63, 717-724 (2008).
109. Biazzo LL, Froshaug DB, Harwell TS et al. Characteristics and abstinence outcomes among tobacco quitline enrollees using varenicline or nicotine replacement therapy. Nicotine Tob. Res. 12, 567-573 (2010).
110. Stapleton JA, Watson L, Spirling LI et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 103, 146-154 (2008). (Pubitemid 350233424)
111. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 2, CD006103 (2011).
112. Rollema H, Hajos M, Seymour PA et al. Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem. Pharmacol. 78, 813-824 (2009).
113. Patterson F, Jepson C, Strasser AA et al. Varenicline improves mood and cognition during smoking abstinence. Biol. Psychiatry 65, 144-149 (2009).
114. Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J. Clin. Psychiatry 70, 1026-1031 (2009).
115. Smith RC, Lindenmayer JP, Davis JM et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr. Res. 110, 149-155 (2009).
116. Sofuoglu M, Herman AI, Mooney M, Waters AJ. Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology (Berl.) 207, 153-162 (2009).
117. Schnoll RA, Shields AE. Physician barriers to incorporating pharmacogenetic treatment strategies for nicotine dependence into clinical practice. Clin. Pharmacol. Ther. 89, 345-347 (2011).
118. US Department of Health and Human Services. Preventing Tobacco Use Among Young People. A Report of the Surgeon General. USDHHS, CDC, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA, USA (1994).
119. Stein RJ, Haddock CK, O'Byrne KK, Hymowitz N, Schwab J. The pediatrician's role in reducing tobacco exposure in children. Pediatrics 106, 1-17 (2000).
120. Emmons KM, Goldstein MG. Smokers who are hospitalized: a window of opportunity for cessation interventions. Prev. Med. 21, 262-269 (1992).
121. Cummings SR, Rubin SM, Oster G. The cost-effectiveness of counseling smokers to quit. JAMA 261, 75-79 (1989). (Pubitemid 19026386)
122. Shields AE, Blumenthal D, Weiss KB, Comstock CB, Currivan D, Lerman C. Barriers to translating emerging genetic research on smoking into clinical practice: Perspectives of primary care physicians. J. Gen. Intern. Med. 20, 131-138 (2005). (Pubitemid 40626990)
123. Shields AE, Levy DE, Blumenthal D et al. Primary care physicians' willingness to offer a new genetic test to tailor smoking treatment, according to test characteristics. Nicotine Tob. Res. 10, 1037-1045 (2008). (Pubitemid 351998440)
124. Shields AE, Lerman C. Anticipating clinical integration of pharmacogenetic treatment strategies for addiction: are primary care physicians ready? Clin. Pharmacol. Therap. 83, 635-639 (2008). (Pubitemid 351417077)
125. Levy DE, Youatt EJ, Shields AE. Primary care physicians' concerns about offering a genetic test to tailor smoking cessation treatment. Genet. Med. 9, 842-849 (2007). (Pubitemid 350295212)
126. Heitjan DF, Asch DA, Ray R, Rukstalis M, Patterson F, Lerman C. Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J. 8, 391-399 (2008).